SEQUENCE LISTING

<110>   SAIKAWA, Akira
         IGARI, Yasutaka
         YAMAMOTO, Yoshio
         HATA, Yoshio

<120>   Sustained-Release Composition, Methods of its Preparation and Use
          Thereof

<130>   2500 US1P

<140>   10/799,320
<141>   2004-03-12

<150>   US 09/582,926
<151>   2000-07-05

<150>   PCT/JP99/00086
<151>   1999-01-13

<150>   JP 10-6412
<151>   1998-01-16

<160>   5

<170>   PatentIn version 3.2

<210>   1
<211>   10
<212>   PRT
<213>   artificial sequence

<220>
<223>   LH-RH peptide derivative/analog

<220>
<221>   MISC_FEATURE
<222>   (1)..(1)
<223>   5-oxo-Pro

<220>
<221>   MISC_FEATURE
<222>   (6)..(6)
<223>   DLeu, DAla, DTrp, DSer(tbut), D2Nal or DHis(ImBzl)

<220>
<221>   MISC_FEATURE
<222>   (9)..(9)
<223>   Pro or Pro-NH-C2H5

<220>
<221>   MISC_FEATURE
<222>   (10)..(10)
<223>   Gly-NH2 or nothing

<400> 1

Pro His Trp Ser Tyr Xaa Leu Arg Pro Xaa
1   5   10

<210> 2
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> LH-RH antagonist derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N(4H2-furoyl)Gly or Nac

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> D2Nal

<220>
<221> MISC_FEATURE
<222> (3)..(3)
<223> D4ClPhe

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> D3Pal

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> NMeTyr, Tyr, Aph(Atz) and NMeAph(Atz)

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> DLys(Nic), DCit, DLys(AzaglyNic), DLys(AzaglyFur), DhArg(Et2),
      DAph(Atz), DhCi.

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> Lys(Nisp), Arg, hArg(Et2).

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> DAlaNH2

2

<400> 2

Xaa Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1   5   10

<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> LH-RH peptide derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> 5-oxo-Pro

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> Dleu

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> Pro-NH-C2H5

<400> 3

Pro His Trp Ser Tyr Xaa Arg Pro
1   5

<210> 4
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> LH-RH peptide derivative/analog

<220>
<221> MISC_FEATURE
<222> (1)..(1)
<223> N-(S)-tetrahydrofur-2-oyl-Gly

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> D2Nal

<220>
<221> MISC_FEATURE
<222> (3)..(3)

```
<223>   D4ClPhe

<220>
<221>   MISC_FEATURE
<222>   (4)..(4)
<223>   D3Pal

<220>
<221>   MISC_FEATURE
<222>   (6)..(6)
<223>   NmeTyr

<220>
<221>   MISC_FEATURE
<222>   (7)..(7)
<223>   DLys(Nic)

<220>
<221>   MISC_FEATURE
<222>   (9)..(9)
<223>   Lys(Nisp)


<220>
<221>   MISC_FEATURE
<222>   (11)..(11)
<223>   DAlaNH2

<400>   4

Gly Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa
1                   5                   10


<210>   5
<211>   9
<212>   PRT
<213>   Artificial Sequence

<220>
<223>   LH-RH peptide derivative/analog

<220>
<221>   MISC_FEATURE
<222>   (1)..(1)
<223>   5-oxo-Pro

<220>
<221>   MISC_FEATURE
<222>   (6)..(6)
<223>   Dleu

<220>
<221>   MISC_FEATURE
<222>   (9)..(9)
<223>   Pro-NH-C2H5
```

<400> 5

Pro His Trp Ser Tyr Xaa Leu Arg Pro
1   5